China Resources Pharmaceutical's (HKG:3320) attributable profit fell to 3.35 billion yuan in 2024 from 3.85 billion yuan in 2023, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share at the drug company decreased to 0.53 yuan from 0.61 yuan in the previous year.
Revenue grew to 257.7 billion yuan from 244.7 billion yuan a year earlier.
The company declared a final dividend of 0.052 yuan per share, payable July 14 to shareholders on record as of June 2.
Shares fell 4% during Wednesday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.